Li, Hu <br/><br/>
A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.  [electronic resource] 

 -  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie  Aug 2019 
 - 108976 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1950-6007 
<br/><br/><label>Standard No.: </label>10.1016/j.biopha.2019.108976  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--pharmacology<br/>Carbamates<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--pharmacology<br/>Intracellular Space--virology<br/>Pyrrolidines<br/>Recurrence<br/>Simeprevir--pharmacology<br/>Sofosbuvir--pharmacology<br/>Valine--analogs & derivatives<br/>Virus Replication--drug effects